Provider review
LevelsRx review
Three plans, three starting figures, and no molecule attached to any of them.
Publishing three monthly figures before an intake puts it ahead of the sellers that publish nothing. None of them is connected to a molecule or a dose, so the gap between them cannot be explained.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
LevelsRx
From $150/mo and $240/mo, neither tied to a molecule
- Vs median
- $19/mo below the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
Publishing anything at all before an intake puts LevelsRx ahead of a real share of this category, and it publishes three monthly figures. The trouble is that none of them is attached to anything. Semaglutide and tirzepatide are both named somewhere on the site, but neither is tied to a specific plan, so a reader looking at the cheaper figure and the dearer one cannot tell whether the gap between them is the difference between the two drugs, between two dose tiers, or between two levels of service. Every figure is also a starting point, with nothing published about what it starts from — not a dose, not a plan length, not a first month. Put those together and the numbers stop being prices and become a range with no axis. For the question this site exists to answer, a floor with no dose behind it is the least useful shape published pricing can take: it tells you the cheapest thing might cost this much, without telling you what the cheapest thing is. No pharmacy is named and no state coverage is published either.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want at least some figures visible before committing to an intake.
- You want both molecules named on the site rather than an unspecified GLP-1.
- You are scanning the low end of the market and want the entry figure.
Look elsewhere if
- You need to know which drug a plan contains. No molecule is attached to any figure.
- You are pricing a dose. Every figure is a starting point with nothing published behind it.
- You want a named pharmacy or a stated coverage area. Neither is published.
What it actually costs
Price as published
Weight-loss plans quoted "starting at $150/month" and "starting at $240/month", with a third metabolic plan also "starting at $150/month" · every figure is a floor and nothing published says what it starts from — not a dose, not a plan length, not a first month · semaglutide and tirzepatide are both named on the site but neither is attached to a specific figure, so a reader cannot tell which plan carries which molecule · no compounding pharmacy is named and no state coverage is published
- Vs median
- $19/mo below the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. Three monthly figures are published and none is attached to a molecule, so a reader cannot tell whether the gap between them is the two drugs, two dose tiers or two service levels. Every one is a "starting at" with no dose behind it. No low-dose product is offered.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- Publishes three monthly figures before any intake rather than gating them behind a quiz.
- Names both molecules on the site rather than selling an unspecified GLP-1.
- The entry figure is at the lower end of the field.
Pharmacy, labs and oversight
LevelsRx dispenses through a Not named facility. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
2 of 4 published openly
What LevelsRx publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Published
- A price you can read before intakeThe figure appears only after an intake quiz, so it cannot be compared before signing up.
- Not published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
LevelsRx publishes three monthly figures before any intake, which puts it ahead of the part of this category that publishes nothing. What it does not do is connect any of them to anything. Each price is a "starting at", so each is a floor of unstated depth. Semaglutide and tirzepatide are both named somewhere on the site, but neither is attached to a particular plan, so a reader looking at $150 and $240 cannot tell whether the gap is the difference between the two molecules, between two dose tiers, or between two service levels. No dose appears behind any figure. For the question this site exists to answer — what does it cost to hold a small dose — there is nothing here to work with beyond a floor, and a floor without a dose is the least useful shape a published price can take.
The honest cons
Every figure is a "starting at" with nothing published about what it starts from.
- No molecule is attached to any specific plan, so the price gap cannot be explained.
- No dose, no named pharmacy and no state coverage published.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
LevelsRx is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#181 of 373
Ordered with the companies that pay us first, and LevelsRx is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- What the evidence actually shows
- The true annual cost of a plan
- What a flat price costs at a low dose
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.